|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
|
|
|
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
|
|
|
Michael Neely introduces a unique technology platform and provides examples of how it has solved difficult formulation problems while adding significant commercial value to the resulting drug products.
|
|
|
Bryan Kobel, CEO of TC BioPharm, discusses his company’s upcoming plans, therapeutic clinical trials, and the biotech landscape.
|
|
|
|
|
|
|
|
|

Founded in 1946, Wirthwein Medical GmbH & Co. KG is today a high-performance system supplier in plastics processing and a development partner for plastic-based and customer-specific product solutions. Focusing on quality and innovation, Wirthwein Medical has also internationally made its mark in the diagnostics, medical technology, pharmaceutics industries – with high-precision, components, packaging, and systems. In addition, proprietary products in the pharmaceutical sector complement the product portfolio. Click here for more.
|
|
|
|
|
|
 |
|
With 29 additional targets the range also includes dog, cow, and pig targets to support translational models in veterinary immunology research….
|
|
 |
|
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations…..
|
|
 |
|
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, recently announced global biopharmaceutical company and cell therapy….
|
|
 |
|
Vaxxas recently announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 60,000-sq-ft Vaxxas Biomedical Facility will serve as….
|
|
|
|
|
|
|
|
 |
|
In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.
Considerations include the …
|
|
 |
|
By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing
Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for …
|
|
 |
|
Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability, solubility, …
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …
|
|
|
|
|
Upcoming eNewsletter Features:
September 6 – API Synthesis
September 13 – Bioavailability
|
|
|
|
|
|
|
|